PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES

• A. Zeidan,
• V. Divino,
• M. DeKoven,
• D. Shah,
• E. Wang,
• D. Bey,
• T. Salimi,
• R. Epstein

Affiliations

A. Zeidan

1 Hematology, Yale University and Yale Cancer Center, New Haven, CT

V. Divino

2 Real World Insights, IQVIA, Falls Church, VA

M. DeKoven

2 Real World Insights, IQVIA, Falls Church, VA

D. Shah

2 Real World Insights, IQVIA, Falls Church, VA

E. Wang

2 Real World Insights, IQVIA, Falls Church, VA

D. Bey

3 Taiho Oncology, Inc., Princeton, NJ

T. Salimi

3 Taiho Oncology, Inc., Princeton, NJ

R. Epstein

4 Epstein Health, Woodcliff Lake, NJ, United States of America